Format

Send to

Choose Destination
J Comp Eff Res. 2017 Oct;6(7):563-574. doi: 10.2217/cer-2017-0015. Epub 2017 Sep 19.

Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1.

Author information

1
Institute of Public Health, Medical Decision Making & Health Technology Assessment, Department of Public Health, Health Services Research & Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics & Technology, Hall in Tirol, Austria.
2
ONCOTYROL, Division of Health Technology Assessment & Bioinformatics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria.
3
Department of Obstetrics & Gynaecology, Medical University of Innsbruck, Innsbruck, Austria.
4
Department of Medical Statistics, Informatics & Health Economics, Medical University of Innsbruck, Innsbruck, Austria.
5
Center for Health Decision Science, Department of Health Policy & Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
6
Institute for Technology Assessment & Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Abstract

AIM:

To develop a prognostic score for primary breast cancer patients integrating conventional predictors and the novel biomarker CHAC1 to aid adjuvant chemotherapy decisions.

PATIENTS & METHODS:

A prognostic score for overall survival was developed using: conventional predictors from a dataset of 1777 patients and the weight of CHAC1 mRNA expression from an independent dataset of 106 patients using multivariate Cox regression.

RESULTS:

The new score includes: CHAC1 mRNA expression, age, tumor size, HER2 neu status, lymph node status and degree of malignancy. Using a cut-off value of 11 score points, 10-year survival was 82% in low-risk (n = 34) and 43% in high-risk patients (n = 72). The addition of CHAC1 resulted in 16% reclassification.

CONCLUSION:

Including CHAC1 in prognostic prediction may aid (and change) personalized treatment selection.

KEYWORDS:

CHAC1 mRNA; adjuvant chemotherapy; biomarker; breast cancer; decision aid; prognostic score

PMID:
29091014
DOI:
10.2217/cer-2017-0015

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center